Atea Pharmaceuticals Story

AVIR -- USA Stock

USD 75.36 5.93 7.29%

Macroaxis Story

Atea Pharmaceuticals Quick Ratio is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Quick Ratio of 17.91. As of 01/30/2021, Enterprise Value over EBIT is likely to grow to 1.24, while Revenue Per Employee is likely to drop slightly above 1 M. While many traders today are more concerned about the preservation of capital over market returns, Atea Pharmaceuticals could be one exception. What exactly are Atea Pharmaceuticals shareholders getting in March? In this post, I will also go over some essential variables affecting Atea Pharmaceuticals' products, and show how it may impact the firm outlook for active traders this year.

Published over three weeks ago

View all stories for Atea Pharmaceuticals | View All Stories

Atea Pharmaceuticals (NASDAQ:AVIR) continues to spike

Atea Pharmaceuticals holds a performance score of 19 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.2259, which signifies a somewhat significant risk relative to the market. Let's try to break down what Atea Pharmaceuticals's beta means in this case. As returns on the market increase, returns on owning Atea Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Atea Pharmaceuticals is expected to outperform it. Although it is essential to pay attention to Atea Pharmaceuticals historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy in foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Atea Pharmaceuticals expected return of 1.64 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Atea Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to analyze future returns on Atea Pharmaceuticals.

How important is Atea Pharmaceuticals's Liquidity

Atea Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Atea Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Atea Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Atea Pharmaceuticals's total debt and its cash.

How Atea Pharmaceuticals utilizes its cash?

To perform a cash flow analysis of Atea Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Atea Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Atea Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Atea Pharmaceuticals Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Net Cash Flow from Operations of (11.53 Million)

What did Atea Pharmaceuticals file with SEC?

The SEC filings are financial statements or other formal documents of Atea Pharmaceuticals that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.

Please check here for more information.

Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Atea Pharmaceuticals shareholders may or may not be submitted as SEC does not always require it.

	16th of February 2021 Unclassified Corporate Event	View
	5th of November 2020 Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year	View

Breaking down Atea Pharmaceuticals Indicators

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Atea Pharmaceuticals has an asset utilization ratio of 7.96 percent. This connotes that the company is making $0.0796 for each dollar of assets. An increasing asset utilization means that Atea Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Our take on today Atea Pharmaceuticals spike

The risk adjusted performance is down to 0.27 as of today. Atea Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Atea Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Atea Pharmaceuticals volatility.

Our Final Take On Atea Pharmaceuticals

While many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Atea Pharmaceuticals may offer a potential longer-term growth to retail investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor drop any shares of Atea Pharmaceuticals at this time. The Atea Pharmaceuticals risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Atea Pharmaceuticals.

About Contributor

Gabriel Shpitalnik is a Member of Macroaxs Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Atea Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC